Clinical Trial Update: A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC [Phase 2]

View source ↗

Summary

A Phase II trial evaluating Eloxatin (oxaliplatin) and Alimta (pemetrexed) in combination with Bevacizumab in advanced non-squamous non-small cell lung cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Bevacizumab (bevacizumab)
• Eloxatin (oxaliplatin)

Snippet

Sponsor: Veeda Oncology | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED